Barclays
SOPH icon

Barclays’s SOPHiA GENETICS SOPH Stock Holding History

Barclays’s Portfolio SOPH Stock Details SOPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.4K Buy
+2,677
New +$13.6K ﹤0.01% 4633
2022
Q3 		– Sell
-57,751
Closed -$209K – 5115
2022
Q2 		$209K Buy
+57,751
New +$293K ﹤0.01% 3393

Other funds holding SOPH

GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $5.12B AUM 19.08% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

Barclays's SOPH Position: Q2 2026 in Review

Barclays opened a new position in SOPHiA GENETICS (SOPH) in Q2 2026: 2,677 shares worth $15.4K. The stake represents ﹤0.01% of the portfolio and ranks #4633 among its holdings. This is a return to the name: Barclays previously reported a position in SOPH as recently as Q2 2022.

Barclays first reported a position in SOPH in Q2 2022 and has held it in 2 quarters since. The position peaked at $209K in Q2 2022. 72 funds tracked by Wall St. Rank hold SOPH as of Q2 2026.

  • Barclays held 2,677 shares of SOPHiA GENETICS worth $15.4K as of Q2 2026.
  • SOPHiA GENETICS was a new Barclays position in Q2 2026.
  • SOPHiA GENETICS made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4633 holding.
  • Barclays first reported a position in SOPHiA GENETICS in Q2 2022 and has held it in 2 quarters since.
  • Barclays's SOPHiA GENETICS position peaked at $209K in Q2 2022.
  • 72 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.